Curis Lifesciences Ltd vs Gujarat Themis Biosyn Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Curis Lifesciences Ltd is ₹ 116.5 as of 06 May 15:30 . The P/E Ratio of Curis Lifesciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 years The Market Cap of Curis Lifesciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 years The Revenue of Curis Lifesciences Ltd is ₹ 9.12 crore as of Jun '24 .The Revenue of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Curis Lifesciences Ltd is ₹ 2.73 crore as of Jun '24 .The EBITDA of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Curis Lifesciences Ltd is ₹ 1.2 crore as of Jun '24 .The Net Profit of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 . The Dividend Payout of Curis Lifesciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 years .

About Curis Lifesciences Ltd

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of 'M/s Loreto Pharmaceutacals', pursuant to a Deed of Partnership dated 2 June, 2010.
Thereafter ' M/s Loreto Pharmaceutacals' was converted from Partnership Firm to a Private Limited Company as 'Curis Lifesciences Private Limited' and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.
Subsequently, Company was converted into a Public Limited Company and the name of the Company was changed from 'Curis Lifesciences Private Limited' to 'Curis Lifesciences Limited' vide certified incorporated upon the conversion dated August 9, 2024, issued by the Central Processing Centre, Manesar. Company's business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic.

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

FAQs for the comparison of Curis Lifesciences Ltd and Gujarat Themis Biosyn Ltd

Which company has a larger market capitalization, Curis Lifesciences Ltd or Gujarat Themis Biosyn Ltd?

Market cap of Curis Lifesciences Ltd is 94 Cr while Market cap of Gujarat Themis Biosyn Ltd is 4,125 Cr

What are the key factors driving the stock performance of Curis Lifesciences Ltd and Gujarat Themis Biosyn Ltd?

The stock performance of Curis Lifesciences Ltd and Gujarat Themis Biosyn Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Curis Lifesciences Ltd and Gujarat Themis Biosyn Ltd?

As of May 6, 2026, the Curis Lifesciences Ltd stock price is INR ₹116.5. On the other hand, Gujarat Themis Biosyn Ltd stock price is INR ₹378.6.

How do dividend payouts of Curis Lifesciences Ltd and Gujarat Themis Biosyn Ltd compare?

To compare the dividend payouts of Curis Lifesciences Ltd and Gujarat Themis Biosyn Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.